

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/BF5AFE061DEEN.html>

Date: July 2018

Pages: 129

Price: US\$ 3,500.00 (Single User License)

ID: BF5AFE061DEEN

Abstracts

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'BDNF NT 3 Growth Factors Receptor - Pipeline Review, H2 2018'; BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 21 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation.

The report 'BDNF NT 3 Growth Factors Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 7 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Cardiovascular, Ear Nose Throat Disorders, Metabolic Disorders and Ophthalmology which include indications Alzheimer's Disease, Solid Tumor, Non-Small Cell Lung Cancer, Breast Cancer, Amyotrophic Lateral Sclerosis, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Colorectal Cancer, Fibrosarcoma, Gastrointestinal Stromal Tumor (GIST), Huntington Disease, Metastatic Colorectal Cancer, Multiple Sclerosis, Neuroblastoma, Parkinson's Disease, Renal Cell Carcinoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Biliary Tumor, Bladder Cancer, Brain Tumor, Cancer Pain, Carcinoid Tumor, Cervical Cancer, Charcot-Marie-Tooth Disease, Depression, Diabetic Retinopathy, Endometrial Cancer, Epilepsy, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioma, Head And Neck Cancer, Hearing Disorders, Hepatocellular Carcinoma, Ischemic Optic Neuropathy, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Major Depressive Disorder, Melanoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroendocrine

Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Neurology, Non-Hodgkin Lymphoma, Non-Rhabdomyosarcoma, Non-Small Cell Lung Carcinoma, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rett Syndrome, Rhabdomyosarcoma, Sarcomas, Stroke, Synovial Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)

The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase

Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Overview

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

AstraZeneca Plc

Boehringer Ingelheim GmbH

Celon Pharma SA

Chronos Therapeutics Ltd

Daiichi Sankyo Co Ltd

Exelixis Inc

Handok Inc

Ignyta Inc

Loxo Oncology Inc

MimeTech Srl

Otonomy Inc

Plexxikon Inc

Takeda Pharmaceutical Co Ltd

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase

Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Drug Profiles

ACD-855 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Agonize TrkB for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-7451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNN-27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-6051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larotrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-22A4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-22B10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTO-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-0131304 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize NTRK2 for Depression - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize TrkA and TrkB for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize TRKB for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize TrkB for CNS Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Dormant Products

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Discontinued Products

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jul 04, 2018: Ipsen reports positive results from CELESTIAL trial for HCC

Jun 04, 2018: NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

Jun 03, 2018: Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018

Jun 01, 2018: Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metastatic Solid Tumors

May 29, 2018: Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX (cabozantinib) in previously Treated Advanced Hepatocellular Carcinoma

May 29, 2018: Ipsen Announces Clinical Data on Cabometyx to Be Presented at ASCO Demonstrating Its Commitment to Patients with Cancer

May 29, 2018: U.S. FDA accepts larotrectinib New Drug Application and grants priority review

May 17, 2018: European Commission approves Ipsen's Cabometyx (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma

May 17, 2018: Bayer Provides Update on larotrectinib at ASCO 2018

Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting

Mar 28, 2018: Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx, for patients with previously treated advanced Hepatocellular Carcinoma (HCC)

Mar 26, 2018: Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer

Mar 23, 2018: Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma

Mar 15, 2018: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma

Feb 21, 2018: Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.4), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Products under Development by Companies, H2 2018 (Contd.6), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Addex Therapeutics Ltd, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Celon Pharma SA, H2 2018
Pipeline by Chronos Therapeutics Ltd, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Exelixis Inc, H2 2018
Pipeline by Handok Inc, H2 2018
Pipeline by Ignyta Inc, H2 2018
Pipeline by Loxo Oncology Inc, H2 2018
Pipeline by MimeTech Srl, H2 2018
Pipeline by Otonomy Inc, H2 2018
Pipeline by Plexxikon Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Addex Therapeutics Ltd

AstraZeneca Plc

Boehringer Ingelheim GmbH

Celon Pharma SA

Chronos Therapeutics Ltd

Daiichi Sankyo Co Ltd

Exelixis Inc

Handok Inc

Ignyta Inc

Loxo Oncology Inc

MimeTech Srl

Otonomy Inc

Plexxikon Inc

Takeda Pharmaceutical Co Ltd

I would like to order

Product name: BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/BF5AFE061DEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BF5AFE061DEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970